Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts

BACKGROUND: Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on eosinophils. Both therapies reduce oral cort...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghassemian, Arian, Park, Jane Jiyoon, Tsoulis, Michael W., Kim, Harold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789431/
https://www.ncbi.nlm.nih.gov/pubmed/33407869
http://dx.doi.org/10.1186/s13223-020-00507-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789431/
https://www.ncbi.nlm.nih.gov/pubmed/33407869
http://dx.doi.org/10.1186/s13223-020-00507-0

Ejemplares similares